These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26097154)

  • 1. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
    Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.
    Bergamaschi MM; Karschner EL; Goodwin RS; Scheidweiler KB; Hirvonen J; Queiroz RH; Huestis MA
    Clin Chem; 2013 Mar; 59(3):519-26. PubMed ID: 23449702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
    Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
    Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
    Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
    Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.
    Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Herning RI; Cadet JL; Huestis MA
    J Anal Toxicol; 2009 Oct; 33(8):469-77. PubMed ID: 19874654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?
    Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Pope HG; Herning R; Cadet JL; Huestis MA
    Addiction; 2009 Dec; 104(12):2041-8. PubMed ID: 19804462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.
    Schwope DM; Bosker WM; Ramaekers JG; Gorelick DA; Huestis MA
    J Anal Toxicol; 2012 Jul; 36(6):405-12. PubMed ID: 22589524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.
    Lee D; Bergamaschi MM; Milman G; Barnes AJ; Queiroz RH; Vandrey R; Huestis MA
    J Anal Toxicol; 2015 Oct; 39(8):580-7. PubMed ID: 26378131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?
    Desrosiers NA; Lee D; Concheiro-Guisan M; Scheidweiler KB; Gorelick DA; Huestis MA
    Clin Chem; 2014 Feb; 60(2):361-72. PubMed ID: 24185550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.
    Lowe RH; Abraham TT; Darwin WD; Herning R; Cadet JL; Huestis MA
    Drug Alcohol Depend; 2009 Nov; 105(1-2):24-32. PubMed ID: 19631478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
    Karschner EL; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
    Drug Alcohol Depend; 2012 Oct; 125(3):313-9. PubMed ID: 22464363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
    Schwope DM; Karschner EL; Gorelick DA; Huestis MA
    Clin Chem; 2011 Oct; 57(10):1406-14. PubMed ID: 21836075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):690-701. PubMed ID: 26257143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.
    Fabritius M; Chtioui H; Battistella G; Annoni JM; Dao K; Favrat B; Fornari E; Lauer E; Maeder P; Giroud C
    Anal Bioanal Chem; 2013 Dec; 405(30):9791-803. PubMed ID: 24202191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking.
    Skopp G; Pötsch L
    J Anal Toxicol; 2008 Mar; 32(2):160-4. PubMed ID: 18334100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration.
    Newmeyer MN; Swortwood MJ; Taylor ME; Abulseoud OA; Woodward TH; Huestis MA
    J Appl Toxicol; 2017 Aug; 37(8):922-932. PubMed ID: 28138971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
    Schwilke EW; Schwope DM; Karschner EL; Lowe RH; Darwin WD; Kelly DL; Goodwin RS; Gorelick DA; Huestis MA
    Clin Chem; 2009 Dec; 55(12):2180-9. PubMed ID: 19833841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.
    Anizan S; Milman G; Desrosiers N; Barnes AJ; Gorelick DA; Huestis MA
    Anal Bioanal Chem; 2013 Oct; 405(26):8451-61. PubMed ID: 23954944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.